eXegenics (Miami) said that it has completed its name change to Opko Health.
The company also announced its common stock has been approved for listing on the AMEX. Opko's stock is expected to begin trading on the AMEX exchange under the ticker symbol OPK.
"Now that we are officially Opko Health, it is fitting that our shares have been approved for listing on the American Stock Exchange," said Dr. Philip Frost, CEO/chairman of Opko Health.
"The improved visibility and liquidity available to us as an AMEX-listed company should contribute to our efforts to advance our ophthalmic businesses and build shareholder value," Frost added.
This approval is contingent upon Opko being in compliance with all applicable listing standards on the date it begins trading on the exchange, and may be rescinded if the company is not in compliance with such standards.
Opko's product portfolio includes the gene silencing agent bevasiranib, which has successfully completed Phase II clinical trials for wet age-related macular degeneration and diabetic macular edema.